Expression of galanin and its receptor subtypes in human breast cancer

doi:10.3969/j.issn.1006-7795.2016.02.020

Abstract

Abstract: Objective To determine the expression of galanin(GAL) and galanin receptor 1、2、3 (GALR1、2、3) in breast cancer and the paired peritumoral tissues; To analyze the relationship between the different clinical therapies and the expression of galanin and its receptor subtypes. Methods qRT-PCR was performed to detect the mRNA level of galanin and its three receptor subtypes in breast cancer and the paired peritumoral tissues. Western blotting was carried out to detect the GAL protein level in breast cancer and the paired peritumoral tissues. t-test was used to analyze the expression of galanin and its three receptor subtypes in cancer tissues of different groups; while paired t-test was performed to analyze the expression of galanin and its three receptor subtypes in breast cancer and the paired peritumoral tissues of the same group. Results The GAL mRNA and protein levels of cancer tissues were higher than the paired peritumoral tissues in the group of no preoperative treatment (P<0.05, P<0.01), whereas the mRNA levels of GALR1, GALR2 and GALR3 were lower than the paired peritumoral tissue (P<0.05, P<0.05, P<0.01). In the NAC and HIFU groups, there were no significant differences in GAL protein, GAL and its receptors mRNA levels between the cancer and the paired peritumoral tissues (P<0.05, P<0.05, P<0.01). However, the GAL protein and GAL mRNA levels were lower than the group of no preoperative treatment (P<0.05). In addition, the GALR3 mRNA level was higher than the group of no preoperative treatment in the NAC group (P<0.01). Conclusion The abnormal expression of galanin and its receptor subtypes in breast cancer was relevant to different clinical therapies, which might be used as a potential biomarker for breast cancer diagnosis, therapy and prognosis.

Key words: breast cancer, galanin, galanin receptor subtypes

CLC Number:

R739.9

Zhang Shuai, Deng Jiahui, Xu Zhiqing, Qi Xiaodong. Expression of galanin and its receptor subtypes in human breast cancer[J]. Journal of Capital Medical University, 2016, 37(2): 214-218.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.02.020

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I2/214

References

[1] DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013[J]. CA Cancer J Clin, 2014, 64(1):52-62.
[2] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] Ahmed S, Sami A, Xiang J. HER2-directed therapy:current treatment options for HER2-positive breast cancer[J]. Breast Cancer, 2015, 22(2):101-116.
[4] Lang R, Gundlach A L, Kofler B. The galanin peptide family:receptor pharmacology, pleiotropic biological actions, and implications in health and disease[J]. Pharmacol Ther, 2007, 115(2):177-207.
[5] Rauch I, Kofler B. The galanin system in cancer[J]. EXS, 2010, 102:223-241.
[6] Kim K Y, Kee M K, Chong S A, et al. Galanin is up-regulated in colon adenocarcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2007, 16(11):2373-2378.
[7] Ormandy C J, Lee C S, Ormandy H F, et al. Amplification, expression, and steroid regulation of the preprogalanin gene in human breast cancer[J]. Cancer Res, 1998, 58(7):1353-1357.
[8] Chung W, Kwabi-Addo B, Ittmann M, et al. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling[J]. PLoS One, 2008, 3(4):e2079.
[9] Sugimoto T, Seki N, Shimizu S, et al. The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma[J]. Genes Chromosomes Cancer, 2009, 48(2):132-142.
[10] Kanazawa T, Iwashita T, Kommareddi P, et al. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells:activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors[J]. Oncogene, 2007, 26(39):5762-5771.
[11] Kanazawa T, Misawa K, Misawa Y, et al. G-protein-coupled receptors:next generation therapeutic targets in head and neck cancer?[J]. Toxins (Basel), 2015, 7(8):2959-2984.
[12] Norum J H, Andersen K, Sorlie T. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy[J]. Br J Surg, 2014, 101(8):925-938.
[13] Stevenson L, Allen W L, Turkington R, et al. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer[J]. Clin Cancer Res, 2012, 18(19):5412-5426.
[14] Kim J C, Lee H C, Cho D H, et al. Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers[J]. J Cancer Res Clin Oncol, 2011, 137(10):1571-1580.
[15] Huang X, Yuan F, Liang M, et al. M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer[J]. PLoS One, 2012, 7(7):e41632.